Curtis Cooper trained at the University of Saskatchewan (MD 1994). He received certification in Internal Medicine in 1997 and in Infectious Diseases in 1999 while at the University of Manitoba. He completed an HIV Research Fellowship and Masters of Epidemiology in 2002 while at the University of Ottawa. He is currently a Professor with the University of Ottawa, Infectious Diseases Consultant with The Ottawa Hospital Division of Infectious Diseases, Scientist with the Ottawa Health Research Institute, Director of The Ottawa Hospital Viral Hepatitis Program. As a clinical researcher, his research activities encompass viral hepatitis, HIV and vaccine development. His work is focused on the development of new therapeutic agents and the delivery of treatments that maximizes safety, adherence and effectiveness. He also oversees cohort research related to HBV, HCV, HIV and COVID19.
Rana U, Driedger M, Sereda P, Pan S, Ding E, Wong A, Walmsley S, Klein M, Kelly D, Loutfy M, Thomas R, Sanche S, Kroch A, Machouf N, Roy-Gagnon MH, Hogg B, Cooper C, for the Canadian Observation Cohort (CANOC) Collaboration. Clinical and demographic predictors of antiretroviral efficacy in HIV–HBV co-infected patients. JAMMI. 2021;6(2):137-48.
Onofrio FQ, Cooper C, Borgia SM, Vachon ML, Ramji A, Lilly LB, Wong A, Booth J, Sattar I, Morales H, Lee S, Conway B, Feld JJ. Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry. Clin Infect Dis. 2021;72(11):e799-e805.
Cooper C, Driedger M, Wong D, Haylock-Jacobs S, Aziz Shaheen A, Osiowy C, Fung S, Doucette K, Wong A, Barrett L, Conway B, Ramji A, Minuk G, Sebastiani G, Wong P, Coffin CS. Distinct Hepatitis B and HIV co-infected populations in Canada. J Viral Hepat. 2021;28(3):517-27.
Barter L, Cooper CL. The impact of electronic medical record system implementation on HCV screening and continuum of care: a systematic review. Ann Hepatol. 2021;24:100322.
Parmar P, Shafran S, Borgia S, Doucette K, Cooper C. Hepatitis C direct-acting antiviral outcomes in patients 75 years and older. J Gasterol Hepatol Open. 2020;5(2):253-7.
Okwor C, Oh JS, Crawley A, Cooper C, Lee S. Expression of Inhibitory Receptors on T and NK Cells Defines Immunological Phenotypes of HCV Patients with Advanced Liver Fibrosis. iScience. 2020;23(9):101513.
Lepage C, Garber G, Corrin R, Galanakis C, Leonard L, Cooper C. Telemedicine successfully engages marginalized rural hepatitis C patients in curative care. JAMMI. 2020; 5(2): 87-97.
Cooper C, Read D, Vachon ML, Conway B, Wong A, Ramji A, Borgia S, Tam E, Barrett L, Smyth D, Feld JJ, Lee SH, CANUHC Cohort. Hepatitis C virus infection characteristics and treatment outcomes in Canadian immigrants. BMC Public Health. 2020;20(1):7
Rana U, Driedger M, Sereda P, Pan S, Ding E, Wong A, Walmsley S, Klein M, Kelly D, Loutfy M, Thomas R, Sanche S, Kroch A, Machouf N, Roy-Gagnon MH, Hogg R, Cooper CL, Canadian Observational Cohort C. Characteristics and outcomes of antiretroviral-treated HIV-HBV co-infected patients in Canada. BMC Infect Dis. 2019;19(1):982.
Doyle MA, Lee T, Singer J, Crawley A, Klein M, Cooper C. Evaluation of Safety and Effectiveness of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch Followed by Ledipasvir/Sofosbuvir HCV Therapy in HIV-HCV Coinfection. Open Forum Infect Dis. 2019;6(7).
